OXPHOS-IN-2

OXPHOS-IN-2 is an orally active OXPHOS inhibitor. OXPHOS-IN-2 exhibits potent inhibitory activity in PC9 (IC50 = 12.3 nM) and Bxpc-3 cells (IC50 = 250 nM in glucose medium, IC50 = 17.5 nM in galactose medium) . OXPHOS-IN-2 decreases the NADH/NAD+ ratio and reduces ATP levels. OXPHOS-IN-2 induces tumor cells apoptosis by activating reactive oxygen species (ROS) and downregulating the level of Nrf2. OXPHOS-IN-2 can be used for research on cancer such as non-small cell lung cancer and pancreatic cancer[1].

Product Specifications

UNSPSC

12352005

Target

AMPK; Apoptosis; Keap1-Nrf2; Mitochondrial Metabolism; Oxidative Phosphorylation; Reactive Oxygen Species (ROS)

Related Pathways

Apoptosis; Epigenetics; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

FC(F)(F)OC1=CC=C(C2=NOC(C3=NN(CC4=CC=CC(N5CCC(S(=O)(C)=O)CC5)=C4)C(C6CC6)=N3)=N2)C=C1

Molecular Formula

C27H27F3N6O4S

Molecular Weight

588.60

References & Citations

[1] Cao L, et al. Synthesis and evaluation of new 5- (1H-1,2,4-triazol-3-yl) -1,2,4-oxadiazole derivatives and their application as OXPHOS inhibitors. Eur J Med Chem. 2025 Jun 25;297:117903.